Docetaxel/Oxaliplatin/Capecitabine (TEX) triplet followed by continuation monotherapy in advanced gastric cancer
dc.contributor.author | Ostwal, Vikas | en_US |
dc.contributor.author | Bose, Subhadeep | en_US |
dc.contributor.author | Sirohi, Bhawna | en_US |
dc.contributor.author | Poladia, Bhavesh | en_US |
dc.contributor.author | Sahu, Arvind | en_US |
dc.contributor.author | Bhargava, Prabhat | en_US |
dc.contributor.author | Doshi, Vipul | en_US |
dc.contributor.author | Dusane, Rohit | en_US |
dc.contributor.author | Nashikkar, Chaitali | en_US |
dc.contributor.author | Shrikhande, Shailesh V | en_US |
dc.contributor.author | Ramaswamy, Anant | en_US |
dc.date.accessioned | 2020-01-02T06:27:59Z | |
dc.date.available | 2020-01-02T06:27:59Z | |
dc.date.issued | 2018-01 | |
dc.description.abstract | Introduction: Docetaxel/oxaliplatin/capecitabine (TEX) is a commonly used combination chemotherapeutic regimen in advanced gastric cancer (AGC). Application strategies in routine clinical practice are reported in this study. Materials and Methods: Patients diagnosed with AGC, receiving biweekly TEX (docetaxel - 60 mg/m (2)-D1; oxaliplatin - 85 mg/m (2)-D1, and capecitabine 500–625 mg/m (2) orally twice daily for 14 days) between July 2012 and May 2016 were retrospectively analyzed for tolerance, prognostic factors, event-free survival (EFS), and overall survival (OS). The proportion of patients continuing and terminating chemotherapy at various time-points was enumerated. Results: Overall, 208 patients were started on TEX. Median EFS was 6.34 months (95% confidence interval [CI] 5.80–6.87), and median OS was 15.31 (95% CI 12.65–17.96). Post 8 cycles of TEX, further 30 patients (14.4%) were continued on chemotherapy (docetaxel, capecitabine, or TEX) whereas 47 patients (22.6%) were on observation only, and there was a statistically significant difference in the median OS of these two groups (22.55 months vs. 14.89 months; P = 0.028). Raised serum alkaline phosphatase (SAP) levels (>100 U/L) predicted inferior survival (P = 0.006). Conclusion: TEX chemotherapy is a feasible, efficacious triplet regimen that can be used in clinical practice. SAP levels >100 U/L is a poor prognostic factor, as observed in this study. An initial “induction” such as combination chemotherapy regimen followed by monotherapy as continuation requires further evaluation | en_US |
dc.identifier.affiliations | Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India | en_US |
dc.identifier.affiliations | Department of Medical Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK | en_US |
dc.identifier.affiliations | H M Patel Center for Medical Care and Education, Karamsad, Gujarat, India | en_US |
dc.identifier.affiliations | Statistician (Clinical Research Secretariat), Tata Memorial Hospital, Mumbai, Maharashtra, India | en_US |
dc.identifier.affiliations | Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India | en_US |
dc.identifier.citation | Ostwal Vikas, Bose Subhadeep, Sirohi Bhawna, Poladia Bhavesh, Sahu Arvind, Bhargava Prabhat, Doshi Vipul, Dusane Rohit, Nashikkar Chaitali, Shrikhande Shailesh V, Ramaswamy Anant. Docetaxel/Oxaliplatin/Capecitabine (TEX) triplet followed by continuation monotherapy in advanced gastric cancer. Indian Journal of Cancer. 2018 Jan; 55(1): 88-93 | en_US |
dc.identifier.issn | 0019-509X | |
dc.identifier.place | India | en_US |
dc.identifier.uri | https://imsear.searo.who.int/handle/123456789/190325 | |
dc.language | en | en_US |
dc.publisher | Indian Cancer Society | en_US |
dc.relation.issuenumber | 1 | en_US |
dc.relation.volume | 55 | en_US |
dc.source.uri | https://dx.doi.org//10.4103/ijc.IJC_353_17 | en_US |
dc.title | Docetaxel/Oxaliplatin/Capecitabine (TEX) triplet followed by continuation monotherapy in advanced gastric cancer | en_US |
dc.type | Journal Article | en_US |
Files
Original bundle
1 - 1 of 1